Sign in or create an account to add this stock to your watchlist.
About Otonomy (NASDAQ:OTIC)
Otonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OTIC
CUSIPN/A
Phone619-323-2200
Debt
Debt-to-Equity RatioN/A
Current Ratio16.24
Quick Ratio16.24
Price-To-Earnings
Trailing P/E Ratio-1.52
Forward P/E Ratio-2.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.24 million
Price / Sales108.51
Cash FlowN/A
Price / CashN/A
Book Value$3.55 per share
Price / Book1.24
Profitability
EPS (Most Recent Fiscal Year)($2.97)
Net Income$-90,130,000.00
Net Margins-6,316.88%
Return on Equity-58.60%
Return on Assets-53.72%
Miscellaneous
Employees53
Outstanding Shares30,580,000
Otonomy (NASDAQ:OTIC) Frequently Asked Questions
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
How were Otonomy's earnings last quarter?
Otonomy Inc (NASDAQ:OTIC) issued its earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.05. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.46 million. Otonomy had a negative net margin of 6,316.88% and a negative return on equity of 58.60%. Otonomy's revenue for the quarter was down 1.1% compared to the same quarter last year. View Otonomy's Earnings History.
What price target have analysts set for OTIC?
4 brokerages have issued 12 month price objectives for Otonomy's shares. Their predictions range from $8.00 to $15.00. On average, they expect Otonomy's share price to reach $10.00 in the next twelve months. View Analyst Ratings for Otonomy.
Who are some of Otonomy's key competitors?
Some companies that are related to Otonomy include TiGenix (TIG), Achaogen (AKAO), Achillion Pharmaceuticals (ACHN), Evelo Biosciences (EVLO), Zealand Pharma (ZEAL), Insys Therapeutics (INSY), Isotechnika Pharma (AUPH), ObsEva (OBSV), Concert Pharmaceuticals (CNCE), Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Zymeworks (ZYME), ProMetic Life Sciences (PFSCF), Dermira (DERM) and GTX (GTXI).
Who are Otonomy's key executives?
Otonomy's management team includes the folowing people:
- Dr. Jay B. Lichter, Co-Founder & Chairman (Age 56)
- Dr. David Allen Weber, Pres, CEO & Director (Age 58)
- Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 56)
- Dr. Kathie M. Bishop, Chief Scientific Officer (Age 52)
- Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel
Has Otonomy been receiving favorable news coverage?
News articles about OTIC stock have trended positive on Friday, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Otonomy earned a daily sentiment score of 0.42 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Otonomy's major shareholders?
Otonomy's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.77%), Dimensional Fund Advisors LP (3.68%), JPMorgan Chase & Co. (0.87%), Millennium Management LLC (0.38%), Sofinnova Ventures Inc (0.32%) and A.R.T. Advisors LLC (0.21%). Company insiders that own Otonomy stock include Carl Lebel and Eric J Loumeau. View Institutional Ownership Trends for Otonomy.
Which institutional investors are selling Otonomy stock?
Which institutional investors are buying Otonomy stock?
OTIC stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Dimensional Fund Advisors LP, Sofinnova Ventures Inc, Trexquant Investment LP and BlackRock Inc.. View Insider Buying and Selling for Otonomy.
How do I buy shares of Otonomy?
Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Otonomy's stock price today?
One share of OTIC stock can currently be purchased for approximately $4.40.
How big of a company is Otonomy?
Otonomy has a market capitalization of $136.83 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.
How can I contact Otonomy?
Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]
MarketBeat Community Rating for Otonomy (OTIC)
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Otonomy (NASDAQ:OTIC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Otonomy in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 127.27%. The high price target for OTIC is $15.00 and the low price target for OTIC is $8.00. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.50 | 2.50 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.00 | $10.00 | $10.00 | $10.00 |
| Price Target Upside: | 127.27% upside | 98.02% upside | 93.24% upside | 93.24% upside |
Otonomy (NASDAQ:OTIC) Consensus Price Target History
Otonomy (NASDAQ:OTIC) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Otonomy (NASDAQ:OTIC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Otonomy (NASDAQ OTIC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.70%
Institutional Ownership Percentage: 66.47%
Otonomy (NASDAQ OTIC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/26/2017 | Eric J. Loumeau | Insider | Sell | 3,522 | $18.59 | $65,473.98 | |  |
| 11/21/2016 | Carl Lebel | Insider | Sell | 10,625 | $18.07 | $191,993.75 | 13,001 | |
| 12/21/2015 | Carl Lebel | insider | Sell | 21,250 | $28.04 | $595,850.00 | 8,920 | |
| 12/17/2015 | Paul E. Cayer | insider | Sell | 3,000 | $29.70 | $89,100.00 | 9,610 | |
| 12/15/2015 | David Allen Weber | CEO | Sell | 5,208 | $27.25 | $141,918.00 | 17,603 | |
| 12/14/2015 | Robert Michael Savel II | insider | Sell | 5,000 | $26.00 | $130,000.00 | 1,256 | |
| 11/30/2015 | Chau Quang Khuong | Director | Sell | 67,106 | $28.93 | $1,941,376.58 | | |
| 11/24/2015 | Orbimed Advisors Llc | Director | Sell | 200,800 | $28.56 | $5,734,848.00 | | |
| 11/19/2015 | Chau Quang Khuong | Director | Sell | 138,398 | $28.62 | $3,960,950.76 | | |
| 11/17/2015 | Paul E. Cayer | insider | Sell | 3,000 | $28.69 | $86,070.00 | 9,610 | |
| 11/16/2015 | David Allen Weber | CEO | Sell | 5,208 | $28.57 | $148,792.56 | 17,603 | |
| 11/13/2015 | David Allen Weber | CEO | Sell | 10,416 | $30.95 | $322,375.20 | 539 | |
| 11/11/2015 | David Allen Weber | CEO | Sell | 5,208 | $24.95 | $129,939.60 | 539 | |
| 11/11/2015 | Paul E. Cayer | CFO | Sell | 3,000 | $24.95 | $74,850.00 | 9,610 | |
| 9/21/2015 | Carl Lebel | insider | Sell | 21,250 | $24.36 | $517,650.00 | 8,920 | |
| 9/17/2015 | Paul E. Cayer | CFO | Sell | 3,000 | $24.95 | $74,850.00 | 9,610 | |
| 9/15/2015 | David Allen Weber | CEO | Sell | 5,216 | $24.95 | $130,139.20 | 539 | |
| 9/14/2015 | Robert Michael Savel II | insider | Sell | 5,000 | $23.98 | $119,900.00 | 1,256 | |
| 6/15/2015 | Robert Michael Savel II | Insider | Sell | 25,000 | $23.73 | $593,250.00 | | |
| 8/19/2014 | A/S Novo | Insider | Buy | 15,690 | $15.50 | $243,195.00 | | |
| 8/18/2014 | A/S Novo | Insider | Buy | 171,875 | $16.00 | $2,750,000.00 | | |
| 8/18/2014 | Jay Lichter | Director | Sell | 50,001 | $16.00 | $800,016.00 | | |
(Data available from 1/1/2013 forward)
Otonomy (NASDAQ OTIC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Anticipate Otonomy (OTIC) Will Post Quarterly Sales of $300,000.00
www.americanbankingnews.com - May 20 at 3:04 AM |
| Analysts Anticipate Otonomy (OTIC) Will Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - May 18 at 1:42 PM |
 | Report: Exploring Fundamental Drivers Behind Valvoline, KKR & Co., Otonomy, Radian Group, Red Rock Resorts, and ...
globenewswire.com - May 11 at 8:28 AM |
| Otonomy (OTIC) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - May 10 at 3:32 PM |
 | BRIEF-Otonomy Qtrly Loss Per Share $0.37
www.reuters.com - May 10 at 8:25 AM |
 | Otonomy: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:25 AM |
| Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 5:33 PM |
| Otonomy (OTIC) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 8 at 1:32 AM |
| BRIEF-Otonomy To Report First Quarter 2018 Financial Results And Provide Corporate Update
www.reuters.com - May 2 at 8:21 AM |
| Otonomy to Report First Quarter 2018 Financial Results and Provide Corporate Update
finance.yahoo.com - May 2 at 8:21 AM |
| Otonomy (OTIC) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 2:20 AM |
| Otonomy (OTIC) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:43 PM |
| Otonomy (OTIC) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 14 at 7:25 AM |
| Zacks Investment Research Lowers Otonomy (OTIC) to Hold
www.americanbankingnews.com - April 13 at 8:29 AM |
| Otonomy (OTIC) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 13 at 1:41 AM |
| Acacia Pharma Expands US Commercial Operations for BAREMSIS® with Four Key Appointments
globenewswire.com - April 11 at 5:31 PM |
| Otonomy (OTIC) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 9 at 5:21 PM |
| Otonomy (OTIC) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 6 at 9:36 AM |
| Otonomy (OTIC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 10:48 AM |
| Otonomy (OTIC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:06 AM |
| Otonomy (OTIC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:23 PM |
| Otonomy (OTIC) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - March 24 at 12:20 PM |
| JPMorgan Chase & Co. Lowers Otonomy (OTIC) to Underweight
www.americanbankingnews.com - March 19 at 10:58 AM |
| Otonomy Inc (OTIC) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 19 at 1:53 AM |
| Otonomy (OTIC) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 17 at 7:48 PM |
| Zacks Investment Research Downgrades Otonomy (OTIC) to Hold
www.americanbankingnews.com - March 17 at 12:04 PM |
| Otonomy (OTIC) Upgraded by Piper Jaffray Companies to "Overweight"
www.americanbankingnews.com - March 12 at 2:21 PM |
 | Frequency Therapeutics Welcomes Former Otonomy CSO as Executive Vice President of Clinical Development
www.bizjournals.com - March 12 at 9:16 AM |
| Otonomy, Inc. to Host Earnings Call
finance.yahoo.com - March 9 at 6:49 PM |
| Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 9 at 6:49 PM |
 | Otonomy's (OTIC) CEO David Weber on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 8:21 AM |
| Otonomy (OTIC) Releases Earnings Results
www.americanbankingnews.com - March 8 at 9:16 PM |
| Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
www.globenewswire.com - March 8 at 6:42 PM |
| Bogle Investment Management L P DE Takes Position in Otonomy Inc (OTIC)
www.americanbankingnews.com - March 5 at 5:10 AM |
| Hudson Bay Capital Management LP Has $1.11 Million Holdings in Otonomy Inc (OTIC)
www.americanbankingnews.com - March 3 at 12:50 PM |
 | Otonomy (OTIC) Announces FDA Approval of OTIPRIO for Acute ... - StreetInsider.com
www.streetinsider.com - March 3 at 8:17 AM |
| Otonomy (OTIC) Announces FDA Approval of OTIPRIO for Acute Otitis Externa
www.streetinsider.com - March 2 at 6:09 PM |
 | Noteworthy Thursday Option Activity: ILG, OTIC, DERM - Nasdaq
www.nasdaq.com - March 2 at 8:17 AM |
 | March PDUFA Dates: Mark Your Calendar, Biotech Investors (OTIC ... - Benzinga
www.benzinga.com - March 1 at 8:15 AM |
| Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:15 AM |
| PDUFA Watch List For March 2018 - Highlights For Amgen, Bristol-Myers, And Otonomy - Seeking Alpha
seekingalpha.com - March 1 at 8:15 AM |
| Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - March 1 at 8:15 AM |
| Otonomy Inc (OTIC) Stake Increased by DLD Asset Management LP
www.americanbankingnews.com - February 27 at 3:10 PM |
| Brokerages Anticipate Otonomy Inc (OTIC) Will Announce Quarterly Sales of $250,000.00
www.americanbankingnews.com - February 24 at 9:54 AM |
| Zacks: Brokerages Anticipate Otonomy Inc (OTIC) Will Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - February 22 at 3:14 AM |
| Otonomy Inc (OTIC) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 22 at 1:24 AM |
| Otonomy Inc (NASDAQ:OTIC): Financial Strength Analysis
finance.yahoo.com - February 9 at 3:55 PM |
| Zacks: Analysts Anticipate Otonomy Inc (OTIC) Will Post Quarterly Sales of $250,000.00
www.americanbankingnews.com - February 7 at 9:42 AM |
| Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Programs at Upcoming Association for Research in Otolaryngology Meeting
finance.yahoo.com - February 6 at 9:33 AM |
| Otonomy Inc (OTIC) Expected to Post Earnings of -$0.67 Per Share
www.americanbankingnews.com - February 5 at 3:12 AM |
Otonomy (NASDAQ:OTIC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Otonomy (NASDAQ:OTIC) Income Statement, Balance Sheet and Cash Flow Statement
Otonomy (NASDAQ OTIC) Stock Chart for Friday, May, 25, 2018
Loading chart…
